Sumatriptan
Imitrex, Onzetra, Sumatriptan, Tosymra, Treximet, Zembrace (sumatriptan) is a small molecule pharmaceutical. Sumatriptan was first approved as Imitrex on 1992-12-28. It is used to treat cluster headache and migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1D and 5-hydroxytryptamine receptor 1B. In addition, it is known to target 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 7, and 5-hydroxytryptamine receptor 1F.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Imitrex, Imitrex statdose, Onzetra, Sumatriptan (discontinued: Alsuma, Imitrex, Imitrex statdose, Sumatriptan, Sumavel dosepro, Zecuity)
CombinationsSumatriptan naproxen, Treximet (discontinued: Treximet)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sumatriptan succinate
Sumatriptan
Naproxen sodium
+
Sumatriptan succinate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TREXIMET | Currax Pharmaceuticals | N-021926 RX | 2008-04-15 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| imitrex | New Drug Application | 2024-02-21 |
| migraine pack | ANDA | 2017-01-13 |
| migranow | unapproved drug other | 2024-12-13 |
| onzetra xsail | New Drug Application | 2024-04-18 |
| sumansetron | unapproved drug other | 2023-01-11 |
| sumatriptan | ANDA | 2025-10-02 |
| sumatriptan and naproxen sodium | ANDA | 2025-01-02 |
| sumatriptan succinate | ANDA | 2025-08-19 |
| sumatriptan succinate and naproxen sodium | NDA authorized generic | 2024-12-24 |
| sumavel dosepro | New Drug Application | 2014-02-07 |
Show 3 more
Indications
FDA
EMA
Show 5 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Sumatriptan Succinate, Zembrace Symtouch, Tonix Meds | |||
| 10537554 | 2036-01-29 | U-72 | |
| 11364224 | 2036-01-29 | U-72 | |
| Sumatriptan Succinate, Onzetra Xsail, Currax | |||
| 10076614 | 2034-10-20 | DP | |
| 10478574 | 2033-11-04 | U-2404 | |
| 8978647 | 2030-12-06 | DP | |
| 9649456 | 2030-10-21 | DP | U-1719, U-2010, U-2011 |
| 8899229 | 2030-08-18 | DP | |
| 8550073 | 2029-10-22 | DP | |
| 10076615 | 2029-07-30 | U-2010, U-2011, U-2404 | |
| 10722667 | 2028-12-30 | DP | |
| 8875704 | 2028-04-07 | DP | U-1809 |
| 10398859 | 2027-12-19 | DP | |
| 10124132 | 2027-03-06 | DP | U-1719, U-2010, U-2011 |
| 11571531 | 2026-02-23 | U-1809 | |
| 8590530 | 2025-09-15 | DP | U-1809 |
| 9108015 | 2025-09-15 | DP | |
| 7975690 | 2025-08-18 | DP | U-1809 |
| 9119932 | 2024-04-23 | DP | |
| Sumatriptan Succinate, Zecuity, Teva Branded Pharm | |||
| 9327114 | 2032-10-08 | DP | U-1328 |
| 8983594 | 2030-11-19 | DP | U-1328 |
| 8366600 | 2029-04-21 | U-1327 | |
| 9272137 | 2027-09-07 | DP | |
| 7973058 | 2027-04-12 | U-1328 | |
| 8155737 | 2027-04-12 | U-1328 | |
| 8470853 | 2027-04-12 | U-1328 | |
| 8597272 | 2027-04-12 | DP | |
| 9427578 | 2027-04-12 | DP | U-1328 |
| Sumatriptan, Tosymra, Tonix Meds | |||
| 9211282 | 2031-07-19 | DP | U-1719 |
| 9610280 | 2030-06-16 | DP | U-1719 |
| 9974770 | 2030-06-16 | DP | U-1719 |
| 10603305 | 2030-06-16 | DP | U-1719 |
| 11337962 | 2030-06-16 | DP | U-1719 |
| 8268791 | 2026-05-09 | DP | |
| 8440631 | 2026-05-09 | DP | U-1719 |
| 9283280 | 2026-05-09 | DP | |
| Sumatriptan Succinate, Alsuma, Meridian Medcl | |||
| 7811254 | 2027-08-26 | DP | U-1083 |
| Sumatriptan Succinate, Sumavel Dosepro, Endo Ventures Ltd | |||
| 7776007 | 2026-11-22 | DP | |
| 7901385 | 2026-07-31 | DP | |
| 8287489 | 2024-12-06 | DP | |
| Naproxen Sodium / Sumatriptan Succinate, Treximet, Currax | |||
| 7332183 | 2025-10-02 | DP | U-867, U-1719 |
HCPCS
Code | Description |
|---|---|
| J3030 | Injection, sumatriptan succinate, 6 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
Clinical
Clinical Trials
134 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 11 | 11 | 33 | 16 | 29 | 98 |
| Headache | D006261 | — | R51 | — | 6 | 5 | 5 | 9 | 25 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 3 | 1 | 1 | 1 | 6 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | 2 | 1 | 3 |
| Emergencies | D004630 | — | — | — | — | — | 1 | 2 | 3 |
| Cluster headache | D003027 | — | G44.00 | — | — | 1 | 1 | 1 | 3 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | 1 | — | 2 |
| Post-traumatic headache | D051298 | — | G44.3 | — | 1 | — | 1 | — | 2 |
| Post-dural puncture headache | D051299 | — | — | — | — | — | 1 | 1 | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | 1 | — | 1 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | 2 | — | 6 | 8 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | 1 | 1 | — | 3 | 5 |
| Dysmenorrhea | D004412 | — | N94.6 | — | — | 2 | — | — | 2 |
| Personal satisfaction | D010549 | — | — | — | — | 2 | — | — | 2 |
| Dental caries | D003731 | EFO_0003819 | K02 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Secondary headache disorders | D051271 | — | — | — | 1 | — | — | 1 | 2 |
| Prescription drug overuse | D000067490 | — | — | — | 1 | — | — | 1 | 2 |
| Vomiting | D014839 | — | R11.1 | — | 1 | — | — | — | 1 |
| Nausea | D009325 | — | R11.0 | — | 1 | — | — | — | 1 |
| Traumatic brain injuries | D000070642 | — | S06 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 12 | — | — | — | 3 | 15 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | — | 1 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 1 | — | — | — | — | 1 |
| Overweight | D050177 | — | E66.3 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 1 | 1 |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | — | — | — | — | 1 | 1 |
| Synovitis | D013585 | EFO_0008997 | M67.5 | — | — | — | — | 1 | 1 |
| Spasm | D013035 | — | M62.83 | — | — | — | — | 1 | 1 |
| Radiculopathy | D011843 | — | M54.1 | — | — | — | — | 1 | 1 |
| Gout | D006073 | EFO_0004274 | M10 | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Rosacea | D012393 | — | L71 | — | — | — | — | 1 | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sumatriptan |
| INN | sumatriptan |
| Description | Sumatriptan is a sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults. It has a role as a serotonergic agonist and a vasoconstrictor agent. It is a sulfonamide and a member of tryptamines. It is functionally related to a N,N-dimethyltryptamine. It is a conjugate acid of a sumatriptan(1+). |
| Classification | Small molecule |
| Drug class | antimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1 |
Identifiers
| PDB | — |
| CAS-ID | 103628-46-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL128 |
| ChEBI ID | 10650 |
| PubChem CID | 5358 |
| DrugBank | DB00669 |
| UNII ID | 8R78F6L9VO (ChemIDplus, GSRS) |
Target
Agency Approved
HTR1D
HTR1D
HTR1B
HTR1B
Organism
Homo sapiens
Gene name
HTR1D
Gene synonyms
HTR1DA, HTRL
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1D
Protein synonyms
5-HT-1D, 5-HT-1D-alpha, 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled, Serotonin 1D alpha receptor, Serotonin receptor 1D
Uniprot ID
Mouse ortholog
Htr1d (15552)
5-hydroxytryptamine receptor 1D (Q8BUW7)
Alternate
HTR1E
HTR1E
HTR1A
HTR1A
HTR5A
HTR5A
HTR6
HTR6
HTR7
HTR7
HTR1F
HTR1F
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Tosymra – Tonix Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Sumatriptan
+
Naproxen
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Sumatriptan
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,736 documents
View more details
Safety
Black-box Warning
Black-box warning for: Sumatriptan and naproxen sodium, Sumatriptan succinate and naproxen sodium, Treximet
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
25,982 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use